Unleashing Biotech Potential: ATLATL Scientific & Miltenyi Biotec Partnership

ATLATL Scientific and Miltenyi Biotec are celebrating a landmark five-year partnership, marking a journey of collaboration and innovation in the biotech sector. With a strong foundation laid over the years, this partnership has flourished into a dynamic alliance poised to drive significant advancements in biotechnology.

Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources. The collaboration in Singapore builds upon the foundation set by their successful ventures, including the CliniMACS Cell Factory® and the MACS® Innovation & Technology Center, MITC Beijing. As ATLATL Scientific expands its presence into Singapore, Miltenyi Biotec emerges as a key partner, contributing multiple platforms such as CliniMACS Prodigy® and CliniMACS Plus to ATLATL’s incubator at Helios Biopolis. This strategic collaboration underscores Miltenyi Biotec’s commitment to supporting innovative startups and driving technological advancements in the biotech ecosystem.

The partnership between ATLATL Scientific and Miltenyi Biotec was further solidified at AsiaBio 2024, where they co-sponsored the event as booth partners. At the event, both companies signed a Memorandum of Understanding (MOU) to signify their continued partnership and strengthen their ties as they expand their presence in Singapore. This collaboration sets the stage for future joint initiatives aimed at fostering innovation and driving growth in the biotech sector.

Looking ahead, ATLATL Scientific and Miltenyi Biotec are poised to embark on co-research and co-development projects in Singapore. These initiatives will not only bolster both companies’ presence in the local biotech ecosystem but also cement Miltenyi Biotec’s position as a prominent maker of cutting-edge equipment for Cell and Gene Therapy. By combining their strengths and resources, ATLATL Scientific and Miltenyi Biotec aim to drive transformative impact in the biotech industry, both locally and globally.

As they look beyond AsiaBio 2024, ATLATL Scientific and Miltenyi Biotec are committed to further collaborations in different global sites, including China, US, and Europe area. These initiatives underscore their shared vision of driving innovation and advancing biotechnology on a global scale.

The partnership between ATLATL Scientific and Miltenyi Biotec represents a testament to the power of collaboration in driving scientific innovation. As they celebrate five years of partnership, both companies are poised to build upon their achievements and drive even greater impact in the years to come.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”